Anti-apoptotic activity of Bcl-2 is enhanced by its interaction with RTN3

Lei Zhu1, Rong Xiang, Wei Dong

  • 1State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, Wuhan 430072, PR China.

Insights

Reticulon 3 (RTN3) interacts with Bcl-2, an apoptosis inhibitor, on the endoplasmic reticulum. RTN3 binding facilitates Bcl-2 accumulation in mitochondria, modulating its anti-apoptotic function.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Bcl-2 is a key inhibitor of apoptosis, primarily acting at the mitochondria.
  • Reticulon 3 (RTN3) is an endoplasmic reticulum-localized protein involved in cellular functions.
  • The interaction between Bcl-2 and RTN3 and its functional consequences are not well understood.

Purpose of the Study:

  • To investigate the interaction between Bcl-2 and RTN3.
  • To determine the role of RTN3 in modulating Bcl-2's anti-apoptotic activity.
  • To elucidate the mechanism by which RTN3 influences Bcl-2 localization and function.

Main Methods:

  • Co-immunoprecipitation to detect protein-protein interactions.
  • Ectopic expression of Bcl-2 and RTN3 in HeLa cells.
  • Tunicamycin treatment to induce endoplasmic reticulum stress.
  • Subcellular fractionation to isolate microsomal and mitochondrial fractions.
  • Western blotting to detect protein levels.

Main Results:

  • RTN3 interacts with Bcl-2 on the endoplasmic reticulum.
  • Overexpression of Bcl-2 reduces RTN3-induced apoptosis in HeLa cells.
  • Tunicamycin treatment increases endogenous RTN3 levels, leading to enhanced Bcl-2 accumulation in both microsomal and mitochondrial fractions.
  • RTN3 binding promotes Bcl-2 translocation to mitochondria.

Conclusions:

  • RTN3 physically interacts with Bcl-2 at the ER.
  • RTN3 binding mediates the accumulation of Bcl-2 in mitochondria.
  • This interaction modulates the anti-apoptotic activity of Bcl-2, suggesting a novel regulatory pathway.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...